Navigation Links
OXIS International, Inc. Announces Publication of Positive Results of Ergothioneine Safety Study in the Journal 'TOXICOLOGY'

BEVERLY HILLS, Calif., Aug. 19 /PRNewswire-FirstCall/ -- OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI) is proud to announce that an Oxis sponsored safety study of ergothioneine was published online on July 30, 2010 by the prestigious peer reviewed journal, TOXICOLOGY.  The study, utilizing the well known "Ames Test" was conducted by researchers from the American Institute of Biomedical Research (Puyallup, WA) and Toxi-Coop Zrt. (Budapest, Hungary) and clearly demonstrated the absence of any mutagenic effect associated with ergothioneine in the study model. The study will be in print shortly in a special nutraceutical issue of TOXICOLOGY.

In a letter to Dr. Alexander Schauss, lead researcher on the study, Dr. Kendall B. Wallace, PhD,  Managing Editor of TOXICOLOGY, stated, "Your accepted paper is considered to be a significant contribution to the field of toxicology and we appreciate the opportunity to publish it in this journal."

"This study represents the continuing commitment by Oxis to further solidifying the already extensive foundation of safety and efficacy studies supporting the unique nutraceutical compound, ergothioneine," stated Bernie Landes, President of Oxis. "This is an important milestone in our plans to introduce a wide range of proprietary and uniquely beneficial ergothioneine based products, including dietary supplements, functional foods and beverages and personal care products," Landes added.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to provide superior solutions to health challenges associated with oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement.

Forward-Looking Statement

This press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company's filings with the Securities and Exchange Commission.

SOURCE OXIS International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
2. Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
3. Chindex International, Inc. to Report Second Quarter Fiscal 2010 Financial Results
4. Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results
5. Natural Alternatives International, Inc. Announces Filing of Patent Infringement Lawsuit
6. DATATRAK International, Inc. Announces Year-End Backlog
7. New Database from ANSI, AAMI, ASTM International, and DIN Provides Centralized Source of Information for Medical Device Professionals
8. DAVISCO Foods International, Inc. and MEGGLE Group Announce a Joint Venture for the Production of Pharmaceutical Lactose.
9. Lexington International, LLC Receives 2009 U.S. Presidents E Award Recognizing its Export Achievements
10. International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia
11. International Growth Continues: Rhythmlink International, LLC Receives CE Marking & ISO 13485 Certification
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... by Type (Dressings, Therapy Devices, Active Wound Care), Application ... and Geography - Global Forecast to 2020" report ... --> The purpose of this report is ... global advanced wound care market. It involves deep dive ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Italian therapeutic drug monitoring ...
Breaking Medicine Technology:
(Date:11/29/2015)... (PRWEB) , ... November 29, 2015 , ... Effective immediately, ... In addition starting on Black Friday Target is offering a “Buy One Scrub ... This is a rare opportunity to purchase IguanaMed at a discounted price. ...
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Trying to ... has created the COUCH BUDDY. "I conceived of this design due to personal experience ... for couch users. It promotes relaxation and convenience, as well as increases support. It ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved around ... help protect a patient’s overall health. The talk stressed the link between periodontal disease ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component of “Supporting ... Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of approximately 250,000 ... through a vast social media strategy and across a network of top news ...
Breaking Medicine News(10 mins):